LEADER 01725oam  2200433   450 
001 9910713514903321
005 20220415113959.0
024 8 $a30-195
035   $a(CKB)5470000002502518
035   $a(OCoLC)1156626520
035   $a(OCoLC)995470000002502518
035   $a(EXLCZ)995470000002502518
100   $a20200603d2020      ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aExamining oversight reports on the 340B Drug Pricing Program $ehearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fifteenth Congress, second session, on examining oversight reports on the 340B Drug Pricing Program, May 15, 2018
210  1$aWashington :$cU.S. Government Publishing Office,$d2020.
215   $a1 online resource (iii, 46 pages)
225 1 $aS. hrg. ;$v115-240
300   $aAccess ID (govinfo): CHRG-115shrg30195.
320   $aIncludes bibliographical references.
517   $aExamining oversight reports on the 340B Drug Pricing Program 
606   $aDrug accessibility$xGovernment policy$zUnited States
606   $aDrugs$xPrices$xGovernment policy$zUnited States
606   $aPrescription pricing$xGovernment policy$zUnited States
608   $aLegislative hearings.$2lcgft
615  0$aDrug accessibility$xGovernment policy
615  0$aDrugs$xPrices$xGovernment policy
615  0$aPrescription pricing$xGovernment policy
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910713514903321
996   $aExamining oversight reports on the 340B Drug Pricing Program$93549034
997   $aUNINA